NFXF Blog

Mirum Pharmaceuticals has officially enrolled the first participant in its BLOOM Phase 2 clinical study evaluating MRM-3379, a potential new treatment for Fragile X syndrome (FXS).

Sometimes enjoying the holiday season can feel more like surviving. With changes in routine, too many social events, and too little sleep, there are countless unknown variables that might create unique challenges for individuals with Fragile X syndrome.

Jay and Anne Souder have done it again with their annual golf event and fundraiser, “FORE! Fragile X,” and we have the pictures!

Learn how you can help us educate more clinicians about the Fragile X premutation, with a special emphasis on raising awareness for FXPOI, in 2026.

Meet Will, who lives with Fragile X syndrome and participates in research studies. Learn how your gift on Giving Tuesday will help grow the future of Fragile X research.

This research looks at how a child’s level of intellectual disability (ID) — meaning how much their thinking and learning abilities are affected — relates to the types of behavioral challenges they experience if they have Fragile X syndrome (FXS).

CONNECTA Therapeutics is taking a new approach to Fragile X syndrome treatment by boosting the brain’s natural ability to reconnect and adapt.

Harmony Biosciences recently announced results from its Phase 3 RECONNECT study of ZYN002, a cannabidiol (CBD) gel being tested for Fragile X syndrome.

The NFXF joined researchers and clinicians at the 6th International Conference on Fragile X Premutation Associated Conditions in Italy to advance understanding of FXTAS, FXPOI, and related conditions, update treatment recommendations, and strengthen global Fragile X collaboration.